Arcadia Science

Arcadia Science is an evolutionary biology company headquartered in Berkeley, California, in the United States. It was founded in 2021 with what its own materials describe as a long time horizon, aiming to rethink the entire research cycle rather than pursue a single narrow therapeutic program. The company's central premise is that evolution has effectively run the world's largest research and development program, and that the structure it has produced in biology can be used to make biological discovery more systematic and to inform drug development. Arcadia positions itself at the intersection of evolutionary biology, computational biology, and therapeutics. Its stated focus is on developing better ways to predict and test therapeutics, using evolutionary structure to guide efforts across the research and development cycle. Rather than operating as a conventional, closed pharmaceutical developer, Arcadia presents itself as a platform-building organization: as it develops its internal platform, it releases apps, software pipelines, protocols, and other resources to the scientific community. A defining feature of the brand is its commitment to open science. Arcadia states that open science is better science and that it wants its research to be useful, rigorous, and impactful, releasing research early and often to improve its own work. This open, tool-releasing posture distinguishes it from typical stealth-mode biotech startups and is central to its public identity. The company is privately held and, as of the available evidence, does not disclose a parent company or owner. Its public presence is built around its website, where it describes its platform, its tools for researchers, and its research outputs. Because Arcadia was founded relatively recently and communicates primarily through its own channels, many corporate details — such as named founders, investors, and financial information — are not established in the supplied evidence and are therefore not asserted here.

Arcadia Science was founded in 2021, according to the company's own About page. From the outset, it framed its mission around a long time horizon and a desire to rethink the entire research cycle, rather than optimizing a single therapeutic candidate. The founding premise, as described by Arcadia, is that evolution has run the world's largest R&D program and that the structure it has produced in biology can be used to make biological discovery more systematic. The company is based in Berkeley, California, in the United States, a location consistent with its identity as a life-sciences research organization. Its early public activity centered on articulating an evolutionary-biology approach to drug development and on building a platform intended to inform efforts across the research and development cycle. Arcadia has stated that it is developing better ways to predict and test therapeutics, positioning its work at the intersection of evolutionary biology and therapeutic development. A distinctive element of Arcadia's history is its open-science practice. As it develops its platform, the company releases apps, software pipelines, protocols, and other resources to the scientific community. It states that open science is better science and that it releases its research early and often to improve its work. This approach has shaped its public profile as a research organization that shares tools and findings rather than keeping them entirely internal. Because Arcadia was founded recently and communicates largely through its own website, the supplied evidence does not establish named founders, investors, funding rounds, or financial details. What is clear from the available sources is that Arcadia is a privately held, active company headquartered in Berkeley, pursuing an evolution-informed, open-science model of biological research and drug development.

• 2021

  Arcadia Science is founded with a long time horizon to rethink the entire research cycle.

• Arcadia publicly describes its platform as using lessons from evolution to inform drug development.

• Arcadia releases apps, software pipelines, protocols, and other resources to the scientific community as part of its open-science approach.

An evolutionary biology company using lessons from evolution to make biological discovery more systematic and to inform drug development, with a strong open-science orientation.

• Evolution-informed drug discovery platform

  A platform that uses the structure produced by evolution to inform efforts across the research and development cycle and to develop better ways to predict and test therapeutics.

• Open science tools for researchers

  Apps, software pipelines, protocols, and other resources released to the scientific community as the platform is developed.

1. 1Arcadia Sciencearcadiascience.com
2. 2About | Arcadia Sciencearcadiascience.com
3. 3Arcadia Sciencewikidata.org